Background: Acute myeloid leukemia (AML) is a highly heterogenous hematological malignancy. Though there has been substantial progress in understanding of AML biology and identification of new therapeutic targets, treatment of AML has largely remained unchanged over the last couple of decades, with 40% patients not achieving remission with standard chemotherapies. Methods: In this study, we employed an ex-vivo tumor explant model (CANscript   TM   ) to select a treatment course for AML patients. CANscript TM offers a comprehensive system that mimics patient tumor microenvironment. 31 AML patients tumors were analyzed to predict response to cytarabine. We next evaluated azacitidine and panobinostat alone and in combination, as alternate treatment regimens for cytarabine refractory tumors. Results: More than 50% of the treated samples showed response to the combination therapy. In AML, frequent upregulation of DNA-methyltransferase enzymes (DNMTs) have been reported with poor survival. We assessed the level of DNMTs using RNAseq and methylation data (n ¼ 100) from the TCGA database. Data indicated increased expression of DNMT and hyperacetylation of HDACs indicating mechanism of high responsiveness to treatment by epigenetic modulators in these tumors. We further noted hypomethylation of IFNGR1 and IFNGR2 genes in TCGA data suggesting activation of JAK/STAT pathway. Hypomethylation of several gene components of JAK-STAT pathway was correlated with an increased expression of these genes in RNAseq data. 8 out of 12 cytarabine refractory tumors were showed response of which 5 were non-responders to epigenetic modulators. Background: Tyrosine Kinase Inhibitors (TKIs) have rapidly become an established therapy in oncology and have been shown to be effective in a wide variety of solid and hematologic malignancies. Acid-inhibitory drugs (AID) (such as antacids, anti-ulcerous drugs and proton pump inhibitors -PPIs) increase the intragastric pH, which may subsequently decrease TKI solubility, bioavailability, and treatment efficacy. The Observatory of Drugs Bretagne/ Pays de la Loire (B-PL) and the Medical Department of the French Regional Health Insurance (FRHI PL) has made an observational study about TKIs and AIDs concomitant dispensing. Methods: FRHI has made an extract in its database for patients treated with TKIs and AIDs in 2016. Concomitant dispensing is defined as the dispensing of a TKI and AIDs during the same calendar month. To complete the study, a survey about PPIs prescription has been proposed to cancer specialists from B and PL areas during 15 days last December. Results: 2309 patients, mean age of 62.9 y (2-93) have been treated with TKIs in 2016 in the PL area. 6.6 dispensings have been done per patient. 795 pts (34%) had no AID dispensing. 274 pts (12%) had no concomitant dispensing of AID and TKI. 1240 pts (54%) had at least one concomitant dispensing. 67% of these patients had a concomitant dispensing of PPIs and 25% a concomitant prescription throughout the TKI treatment. Among these concomitant takes, 34% showed no interaction, 23% showed interactions (34% unknown cases, 9% diverging data). Data from the Bretagne area will be shown at the meeting. 43 clinicians have answered the survey about PPI prescription: 98% have prescribed them. The major reasons were: treatment of gastroesophageal reflux disease (88%), prevention/treatment of NSAID-associated ulcers (67%) or of esophageal duodenal and stomach ulcers (55%), for unknown reasons (31%), and for Zollinger-Ellison syndrome (31%). Duration of treatment was between 7 days and 2 months. Conclusions: Drug-Drug Interaction (DDI) analyses would be performed to underline for which TKIs, TKIs-PPIs interaction was the most harmful. Clear practice tools Background: Identification of tumor margin during surgery is necessary for limited resection of non-small cell lung cancer (NSCLC). In this study, we developed a novel technique of lung cancer margin visualization by intraoperative inhalation of indocyanine green (ICG) and verified its clinical applicability using mouse and rabbit lung cancer model. Methods: By observing the distribution of the inhaled ICG in each organ (lung, liver, brain, spleen, and kidneys) of mice at five different time intervals, we demonstrated that the inhaled ICG was delivered rapidly and was mainly distributed in the lung tissue. In the mouse model of lung cancer, we confirmed that the inhaled ICG entered the normal lung through phagocytosis by alveolar macrophages of normal lung tissue and rarely spread in lung cancer tissue because of mechanical airway obstruction by the tumor. Results: Therefore, the fluorescent signal of inhaled ICG was mainly visualized in normal lung tissue but not in lung cancer tissue, which could assist in identifying the tumor margin. For clinical applicability, the inhaled dose of ICG was optimized in a rabbit lung cancer model. Compared to intravenous administration, this method accurately defined the tumor margin with 5.3-fold higher detection efficiency when 20 times lower dose of ICG was used. The ICG inhalation technique provided more clear visualization of tumor margin with lower dose and in shorter time during surgery compared to the conventional intravenous injection method. Conclusions: The ICG inhalation technique provided more clear visualization of tumor margin with lower dose and in shorter time during surgery compared to the conventional intravenous injection method. Lung-specific delivery of the clinically approved ICG could be used effectively and safely in real clinical practice in the near future. Legal entity responsible for the study: Korea University. Background: The chemotherapeutic response is still low, and the need for a biomarker to overcome chemo-resistance is necessary. Methods: We performed quantitative proteomics mass spectrometry in paired 20 FFPE biopsy breast cancer samples consist of non-responsive and responsive groups to chemotherapy. For verification of enriched biomarkers and biological pathways, ten human breast cancer cell lines enrolled and verified biological functions through molecular biology-driven assays, including RNAi, celltiter-glo luminescent assay, mitochondrial membrane potential assay (MMPA), IF, exosome uptake assay, time-lapse live cell imaging system, and the 3D tumor spheroid-based function assays. Machine learning analysis using r-caret recursive feature elimination to select and apply them to an independent cohort with 50 FFPE biopsy samples to discover the most optimal combination of immunohistochemical biomarkers to predict chemo-responsiveness. Results: A total of 6,424 proteins were identified and 254 were confirmed to be significantly altered proteins related to chemotherapeutic response. From the patient group with chemo-resistance, we featured 56 upregulated proteins considerably in six closely related subcellular organelles concerning transcellular transportation system based on domain knowledge for text-mining and public network databases for network analysis.
Background: Acute myeloid leukemia (AML) is a highly heterogenous hematological malignancy. Though there has been substantial progress in understanding of AML biology and identification of new therapeutic targets, treatment of AML has largely remained unchanged over the last couple of decades, with 40% patients not achieving remission with standard chemotherapies. Methods: In this study, we employed an ex-vivo tumor explant model (CANscript   TM   ) to select a treatment course for AML patients. CANscript TM offers a comprehensive system that mimics patient tumor microenvironment. 31 AML patients tumors were analyzed to predict response to cytarabine. We next evaluated azacitidine and panobinostat alone and in combination, as alternate treatment regimens for cytarabine refractory tumors. Results: More than 50% of the treated samples showed response to the combination therapy. In AML, frequent upregulation of DNA-methyltransferase enzymes (DNMTs) have been reported with poor survival. We assessed the level of DNMTs using RNAseq and methylation data (n ¼ 100) from the TCGA database. Data indicated increased expression of DNMT and hyperacetylation of HDACs indicating mechanism of high responsiveness to treatment by epigenetic modulators in these tumors. We further noted hypomethylation of IFNGR1 and IFNGR2 genes in TCGA data suggesting activation of JAK/STAT pathway. Hypomethylation of several gene components of JAK-STAT pathway was correlated with an increased expression of these genes in RNAseq data. 8 out of 12 cytarabine refractory tumors were showed response of which 5 were non-responders to epigenetic modulators. Background: Tyrosine Kinase Inhibitors (TKIs) have rapidly become an established therapy in oncology and have been shown to be effective in a wide variety of solid and hematologic malignancies. Acid-inhibitory drugs (AID) (such as antacids, anti-ulcerous drugs and proton pump inhibitors -PPIs) increase the intragastric pH, which may subsequently decrease TKI solubility, bioavailability, and treatment efficacy. The Observatory of Drugs Bretagne/ Pays de la Loire (B-PL) and the Medical Department of the French Regional Health Insurance (FRHI PL) has made an observational study about TKIs and AIDs concomitant dispensing. Methods: FRHI has made an extract in its database for patients treated with TKIs and AIDs in 2016. Concomitant dispensing is defined as the dispensing of a TKI and AIDs during the same calendar month. To complete the study, a survey about PPIs prescription has been proposed to cancer specialists from B and PL areas during 15 days last December. Results: 2309 patients, mean age of 62.9 y (2-93) have been treated with TKIs in 2016 in the PL area. 6.6 dispensings have been done per patient. 795 pts (34%) had no AID dispensing. 274 pts (12%) had no concomitant dispensing of AID and TKI. 1240 pts (54%) had at least one concomitant dispensing. 67% of these patients had a concomitant dispensing of PPIs and 25% a concomitant prescription throughout the TKI treatment. Among these concomitant takes, 34% showed no interaction, 23% showed interactions (34% unknown cases, 9% diverging data). Data from the Bretagne area will be shown at the meeting. 43 clinicians have answered the survey about PPI prescription: 98% have prescribed them. The major reasons were: treatment of gastroesophageal reflux disease (88%), prevention/treatment of NSAID-associated ulcers (67%) or of esophageal duodenal and stomach ulcers (55%), for unknown reasons (31%), and for Zollinger-Ellison syndrome (31%). Duration of treatment was between 7 days and 2 months. Conclusions: Drug-Drug Interaction (DDI) analyses would be performed to underline for which TKIs, TKIs-PPIs interaction was the most harmful. Clear practice tools should be created to help clinicians to evaluate this DDI and what to do for their patients. Guidelines will be presented at the meeting. Legal entity responsible for the study: Cancer Observatory, OMEDIT B and PL. Background: Identification of tumor margin during surgery is necessary for limited resection of non-small cell lung cancer (NSCLC). In this study, we developed a novel technique of lung cancer margin visualization by intraoperative inhalation of indocyanine green (ICG) and verified its clinical applicability using mouse and rabbit lung cancer model. Methods: By observing the distribution of the inhaled ICG in each organ (lung, liver, brain, spleen, and kidneys) of mice at five different time intervals, we demonstrated that the inhaled ICG was delivered rapidly and was mainly distributed in the lung tissue. In the mouse model of lung cancer, we confirmed that the inhaled ICG entered the normal lung through phagocytosis by alveolar macrophages of normal lung tissue and rarely spread in lung cancer tissue because of mechanical airway obstruction by the tumor. Results: Therefore, the fluorescent signal of inhaled ICG was mainly visualized in normal lung tissue but not in lung cancer tissue, which could assist in identifying the tumor margin. For clinical applicability, the inhaled dose of ICG was optimized in a rabbit lung cancer model. Compared to intravenous administration, this method accurately defined the tumor margin with 5.3-fold higher detection efficiency when 20 times lower dose of ICG was used. The ICG inhalation technique provided more clear visualization of tumor margin with lower dose and in shorter time during surgery compared to the conventional intravenous injection method. Conclusions: The ICG inhalation technique provided more clear visualization of tumor margin with lower dose and in shorter time during surgery compared to the conventional intravenous injection method. Lung-specific delivery of the clinically approved ICG could be used effectively and safely in real clinical practice in the near future. Legal entity responsible for the study: Korea University. Background: The chemotherapeutic response is still low, and the need for a biomarker to overcome chemo-resistance is necessary. Methods: We performed quantitative proteomics mass spectrometry in paired 20 FFPE biopsy breast cancer samples consist of non-responsive and responsive groups to chemotherapy. For verification of enriched biomarkers and biological pathways, ten human breast cancer cell lines enrolled and verified biological functions through molecular biology-driven assays, including RNAi, celltiter-glo luminescent assay, mitochondrial membrane potential assay (MMPA), IF, exosome uptake assay, time-lapse live cell imaging system, and the 3D tumor spheroid-based function assays. Machine learning analysis using r-caret recursive feature elimination to select and apply them to an independent cohort with 50 FFPE biopsy samples to discover the most optimal combination of immunohistochemical biomarkers to predict chemo-responsiveness. Results: A total of 6,424 proteins were identified and 254 were confirmed to be significantly altered proteins related to chemotherapeutic response. From the patient group with chemo-resistance, we featured 56 upregulated proteins considerably in six closely related subcellular organelles concerning transcellular transportation system based on domain knowledge for text-mining and public network databases for network analysis.
14 intracellular exosomal transportation markers were identified to control chemosensitivity through siRNA array panel assay. Live cell images showed changed exosomal trafficking in cell lines manipulated by candidate markers. Through the verification step by machine learning analysis, we selected five markers and applied them to an independent cohort with FFPE biopsy samples to discover the most optimal combination of immunohistochemical biomarkers to predict chemo-responsiveness. Conclusions: The present study provides the first evidence to identify a predictive biomarker for chemotherapeutic response based on in-depth proteomics. The newly discovered biomarkers and biological evidence can provide the novel insight to overcome chemoresistance in breast cancer. Legal entity responsible for the study: Han Suk Ryu. Background: Diagnosis and treatment of Cancer of Unknown Origin (CUP) continues to be a challenge. In the era of personalized medicine, genomic profile by NextGeneration-Sequencing (NGS) in addition to immunohistochemistry (IHC) tests may complement clinical features improving diagnosis and detecting targetable mutations. In the present study we have analysed the clinical utility of theOncoDEEPV R CUP platformfor tissue of origin assessment and genotyping in a cohort of CUP patients. Methods: We conducted this multicentric prospective exploratory study across 22 institutions (September 2017 -March 2018 . The cohort included 60 patients with histologically diagnosed metastatic CUP and available FFPE tumor samples. The molecular analysis was performed using the OncoDEEPV R CUP platform, which includes a deep genomic tumor characterization as well as a panel of IHC tests. Results: Patient's median age was 60 years , 61.7% were females. At time of diagnosis,48% presented a single metastatic site whereas 52% has multimetastaticlocations. Predominant histology was adenocarcinoma (36.7%) followed by carcinoma NOS (25%), squamous cell carcinoma (13.3%) and others (25%). In 10% of the cases, the analysis could not be completed due to insufficient tumor samples. In the remaining 54 samples, a probable primary origin was assessed in 43 patients (80%). Potentially actionable mutations were found in 36 cases (61%). As expected, the most frequently mutated gene was TP53 (12/36), followed by KRAS, TPMT, ARID1A,BRAF, CDKN2A, PI3KCA, PTEN and STK11. During follow up 11 deaths have been recorded, whereas the rest of the patients remain in the study. Conclusions: OncoDEEPV R CUP may provide an opportunity for CUP patients to benefit from site-specific treatments and personalized therapies if druggable mutations are identified. Acknowledgments to the rest collaborating centers: H. U. 
